Viral Safety for Biologicals Conference 2014
June 24 - 25, 2014
Cologne , Germania
18+ industry case studies on minimising viral contamination risk including new insights from Eli Lilly and Company, Merck Serono, Regeneron Pharmaceuticals and Novartis Pharma AG.
Independent analysis from Baxter BioScience on the application and implementation of next-generation detection technologies for rapid virus identification.
Genzyme and Sanofi Pasteur evaluate the implementation of upstream viral clearance barriers to reduce the risk of contamination from raw materials and media.
Roche Diagnostics present the first FDA approved viral clearance design space following QbD principles.
NEW interactive strategic panel discussions on dealing with pressure release during nanofiltration and strategies to handle suspected contaminations.
Critical regulatory advice from the FDA and PEI on the use of next-generation detection technologies, in-house data in viral clearance and viral safety standards expected
Independent analysis from Baxter BioScience on the application and implementation of next-generation detection technologies for rapid virus identification.
Genzyme and Sanofi Pasteur evaluate the implementation of upstream viral clearance barriers to reduce the risk of contamination from raw materials and media.
Roche Diagnostics present the first FDA approved viral clearance design space following QbD principles.
NEW interactive strategic panel discussions on dealing with pressure release during nanofiltration and strategies to handle suspected contaminations.
Critical regulatory advice from the FDA and PEI on the use of next-generation detection technologies, in-house data in viral clearance and viral safety standards expected
Eventi correlati
Viral Safety for Biologicals Conference June 24 - 25, 2014
